Dietetic Pattern in Children With Autism Spectrum Disorders

Autism Spectrum Disorder Clinical Trial

Official title:

Gut Microbiota, Nutrition and Adverse Reactions to Food in Children With Autism Spectrum Disorders

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04719923
• Other study ID #: 312/17
• Status: Completed
• Start date: October 1, 2017
• Est. completion date: October 1, 2020

Study information

• Verified date: May 2024
• Source: Federico II University
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

To date, it is well documented that the gut microbiota (GM) influences numerous physiological processes in the healthy "host". The alteration of the composition and function of the intestinal microbiota, commonly referred to as "dysbiosis", is associated with many pathological conditions. The high co-morbidity between inflammatory bowel diseases and psychiatric symptoms such as anxiety and stress and the frequent presence of gastrointestinal dysfunctions in autistic patients have highlighted a possible implication of GM in psychiatric disorders. The ability of GM to communicate with the central nervous system and the possible influence on behavior led to the discovery of the existence of a microbiota-gut-brain axis. Clinical and experimental data suggest a possible role of modifications in the composition and function of the intestinal microbiota (impaired production of short-chain fatty acids, SCFAs) in major psychiatric disorders such as autism spectrum disorders (ASD). ASD is a severe neurological condition characterized by severe stereotypical behaviors and deficits in linguistic and social interaction. The prevalence of ASD in children is continuously increasing in Western countries. The pathogenesis of ASD is still poorly defined. The clinical manifestations of ASD are the result of complex interactions between genetic, epigenetic, environmental and microbiological factors. The improvement in gastrointestinal symptoms of autistic patients after short-term oral treatment with antibiotics and probiotics clearly indicated a role of the metabolites of MI in ASD. In particular, an alteration in the phyla of Bacteroidetes and Firmicutes in fecal samples from autistic children has been described with conflicting results. Williams and colleagues (2011) evaluated a significant increase in the Firmicutes / Bacteroidetes ratio in intestinal biopsies of autistic children with gastrointestinal disorders. It has also been shown in animal models of ASD that dysbiosis is positively associated with an increase in butyrate levels and inversely associated with the "score" of the severity of ASD symptoms. Alterations in nutritional status, eating habits and adverse reactions to food appear to be more frequent in children with ASD. Several studies support the hypothesis that children with ASD have a greater refusal of food, requiring specific food presentations or eating a reduced variety of foods compared to children without ASD. These conditions are associated with dysbiosis. Preliminary data suggest that particular elimination diets and / or modifications of the intestinal microbiota can determine a positive effect on the symptoms of ASD. A better knowledge of the composition and functions of the intestinal microbiota also in relation to eating habits and the presence of adverse reactions to food in the child with ASD could facilitate new effective strategies for the prevention and treatment of these conditions.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 200
• Est. completion date: October 1, 2020
• Est. primary completion date: October 1, 2020
• Gender: All
• Age group: 18 Months to 7 Years

Eligibility

Inclusion Criteria:

• subjects with diagnosis Autism Spectrum Disorder or healthy controls

Exclusion Criteria:

• Concomitant presence of:

• epilepsy

• neurological syndromes,

• immunodeficiencies,

• type 1 diabetes

• endocrine diseases,

• congenital heart disease,

• inborn errors of metabolism,

• tuberculosis,

• cystic fibrosis,

• chronic tract diseases respiratory,

• malignancy,

•Major malformations

• previous surgeries of the gastrointestinal / urinary / respiratory tract

• Use of antibiotics or anti-mycotic and / or pre / pro / synbiotics during the 12 weeks prior to enrollment.

• investigator's uncertainty about the willingness or ability of the subject to comply with the protocol requirements.

Related Conditions & MeSH terms

• Autism Spectrum Disorder
• Autistic Disorder
• Child Development Disorders, Pervasive

Intervention

Behavioral:
• Children with autism spectrum disorders
Subjects affected by autism spectrum disorders

Locations

Country	Name	City	State
Italy	University of Naples Federico II	Naples

Sponsors (1)

Lead Sponsor	Collaborator
Federico II University

Country where clinical trial is conducted

Italy, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Adverse food reactions	The evaluation of the occurrence of food reaction is study population	at enrollment
Secondary	Eating habits	The evaluation of eating habits with the 3-day food diary	at the entrollment
Secondary	Nutritional status	The evaluation of nutritional status with the collection of auxological data	at the entrollment
Secondary	Composition of gut microbiota	The evaluation of intestinal microbiota with the shotgun analysis	at the entrollment
Secondary	Function of gut microbiota	The evaluation of short chain fatty acids with the gascromatography	at enrollment